
Swiss Pharma Firm Sandoz Invests $440 Million In Slovenia
-
Français
fr
Sandoz investit 440 millions de dollars en Slovénie
Original
Read more: Sandoz investit 440 millions de dollars en Slovéni
+Get the most important news from Switzerland in your inbox
The announcement brings current and planned investments in the small Alpine country to more than $1.1 billion by 2029, according to a press release issued on Tuesday by the specialist in generic and biosimilar treatments. These include a new biosimilars production centre in Lendava and a development centre in the capital, Ljubljana.
Sandoz intends to take advantage of an“unprecedented market opportunity”, with patent expiries expected to reach $222 billion over the next ten years. The Group believes it is the leading foreign direct investor in the European country.
More More Swiss pharma's big bet on SloveniaThis content was published on Feb 9, 2024 As Swiss companies Novartis and Sandoz shift to complex, expensive medicine, they are increasingly dependent on the tiny Balkan nation of Slovenia.
Read more: Swiss pharma's big bet on Sloveni
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- FBS Analysts Link Fed Signals To A Potential Crypto Comeback
- Bitmex Study Reveals 90% Drop In Extreme Bitcoin Perpetual Futures Funding Rates Since 2016, Signalling Market Maturation
- SBI VEN CAPITAL INVESTS €1 MILLION IN COLOSSUS DIGITAL's BRIDGE ROUND
- Macroeconomics, Market Shifts, And Trading Speed Take Center Stage At B2MEET By B2PRIME
- GUNZ Announces $GUN Token Expansion To Solana
- Rank Platform Officially Announces TGE And $RAN Listing On MEXC
Comments
No comment